Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radio-chemotherapy with GEMOX for Locally Advanced Pancreatic Cancer
NCT02035072Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Nov 2010
- Primary completion
- Dec 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in pancreatic cancer (PC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Toxicity at 15 months and Proportion of resectable patients at 3 years. Started Nov 2010; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02035072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035072.